Tag: Pharmaceutical Deal

Sobi gained global rights for emapalumab from Novimmune

lab research
Swedish Orphan Biovitrum AB and Novimmune SA have entered into an licence agreement for the global rights to an orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis (HLH).

Novartis buys exclusive rights to a promising dermatologic drug

novartis
Novartis announced that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106.

EUSA Pharma buys global rights to Sylvant drug from Janssen

drugs
EUSA Pharma announced that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland to acquire the global rights to SYLVANT® (siltuximab).

Aurobindo Pharma strengthens its European business

aurobindo
Aurobindo Pharma announced the signing of a definitive agreement to acquire from Apotex International, its commercial operations and certain supporting infrastructure in five European countries.

Akebia Therapeutics and Keryx Biopharmaceuticals will merge

pharma
Akebia Therapeutics and Keryx Biopharmaceuticals announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement.

Otsuka Pharmaceutical will buy US biopharma company

otsuka
Otsuka Pharmaceutical (Japan) and Visterra (USA) announced that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately $430 million.

Sanofi and Advent completed negotiations for the acquisition of Zentiva

zentiva
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion

Yunfeng Capital and Hybio Pharmaceutical acquired German pharma company

test-tubes
A consortium led by Yunfeng Capital and Chinese biopharmaceutical company Hybio Pharmaceutical has entered into an agreement to buy all the shares of German speciality pharmaceutical firm AMW GmbH.

DSM Sinochem Pharmaceuticals to be bought by Bain Capital

DSM Sinochem Pharmaceuticals
Bain Capital Private Equity, a leading global private investment firm, announced that it has signed a definitive agreement to acquire DSM Sinochem Pharmaceuticals (DSP).

Catalent acquired Juniper Pharmaceuticals

tubes
Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has agreed to acquire Juniper Pharmaceuticals.

Biogen expands its ownership in Samsung Bioepis

biogen
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics and Biogen.

Roche pays $2.4 billion to acquire Foundation Medicine

roche
Roche and Foundation Medicine (USA) entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche with a total transaction value of $2.4 billion.

United Therapeutics buys specialty pharmaceutical company SteadyMed

test tube
United Therapeutics Corporation and SteadyMed Ltd announced the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed. The transaction is valued at $216 million.

Takeda will buy Shire for $64 billion

takeda
Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for $64 billion in one of the biggest pharma deals to date.

Advent International will acquire Sanofi’s generics subsidiary Zentiva

zentiva
Advent International and Sanofi have entered into exclusive negotiations under which Advent would acquire Zentiva, Sanofi’s European generics business for €1,919 million.

Servier buys oncology business from Shire

shire
Shire, the leading global biotechnology company focused on rare diseases announced that it has entered into a definitive agreement with to sell its Oncology business for $2.4 billion.